title: [Efficacy of hepatectomy-predominant treatment on stage III A hepatocellular carcinoma: a report of 108 cases].
abstract: OBJECTIVE
  At present, there are controversies in the treatment for stage III A hepatocellular carcinoma (HCC). This study was to explore the efficacy of hepatectomy-predominant treatment on stage III A HCC.
  
  
  METHODS
  From January 2002 till December 2003, 108 stage III A HCC patients were randomized into two groups: 58 underwent hepatectomy (hepatectomy alone group) and 50 underwent hepatectomy with adjuvant transcatheter arterial chemoembolization (TACE) (combination group). The overall survival and tumor-free survival were observed.
  
  
  RESULTS
  The median tumor-free survival for all the patients was 5.0 months (2.0-69.0 months). The 1-, 3- and 5-year tumor-free survival rates were 25.0%, 8.3% and 6.5%, respectively. The median survival for all the patients was 21.0 months (4.0-69.0 months). The 1-, 3- and 5-year overall survival rates were 72.2%, 25.9% and 19.4%, respectively. The median tumor-free survival and 1-, 3-and 5-year tumor-free survival rates for combination group were 7.0 months, 40.0%, 16.0% and 12.0%, respectively; correspondingly, for hepatectomy alone group were 4.0 months, 15.5%, 1.7% and 1.7%, respectively (log-rank=16.01, p < 0.01). The median overall survival, 1-, 3- and 5-year overall survival rates for combination group were 24.5 months, 86.0%, 36.0% and 24.0%, respectively; correspondingly, for hepatectomy alone group were 15.5 months, 60.3%, 17.2% and 13.8%, respectively (log-rank =6.17, p=0.013).
  
  
  CONCLUSIONS
  Hepatectomy-predominant treatment has certain effect on stage III A HCC. Hepatectomy plus adjuvant TACE could improve the survival of stage III A HCC patients.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, P. R. China.
authors.forename: Chong
authors.initials: C
authors.lastname: Zhong
authors.forename: Rong-Ping
authors.initials: RP
authors.lastname: Guo
authors.forename: Min-Shan
authors.initials: MS
authors.lastname: Chen
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.forename: Zhi-Yuan
authors.initials: ZY
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004621:Embolization, Therapeutic; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy / Q000379:methods; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D015996:Survival Rate; D055815:Young Adult